Agios Pharma to discontinue sickle cell disease treatment development
Agios Pharma to discontinue sickle cell disease treatment development July 21 (Reuters) - Agios Pharmaceuticals AGIO.O said on Tuesday it will stop development of its sickle cell disease treatment after results from a mid-stage trial did not establish a differentiated profile to support continued development.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
Recent news on Agios Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Agios Q2 revenue jumps on US commercial launch of AQVESME
Brief: Agios Pharmaceuticals Q2 Product Revenue USD 44.745 Million Vs. IBES Estimate USD 25.5 Million